Tag: RFS
Cell-free DNA measurable residual disease as a predictor of postallogeneic hematopoietic cell transplant outcomes
The measurable residual disease (MRD) assessment provides an attractive predictor of alloHCT outcomes. Cell-free DNA (cfDNA) has been applied to diagnosis, early detection, and disease burden monitoring in various tumors but its utility as an MRD test in myeloid malignancies has not been systematically evaluated. We sought to determine the…
ASCO: Moderna, Merck melanoma vaccine set for phase 3
Moderna’s move into personalised cancer therapy continues to proceed at a rapid pace, with Merck & Co-partnered melanoma vaccine mRNA-4157 heading for a pivotal phase 3 programme after a phase 2b data drop at ASCO. In the study, mRNA-4157 (V940) – which targets dozens of unique tumour-associated antigens or neoantigens…
Moderna and Merck Announce mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab)
mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of distant metastasis or death by 65% (HR=0.347 [95% CI, 0.145-0.828]); one-sided p value=0.0063) compared to KEYTRUDA alone The DMFS results, a key secondary endpoint of the Phase 2b KEYNOTE-942 study, will be presented at the 2023 American Society of Clinical…
Immune-related transcripts, microbiota and vector competence differ in dengue-2 virus-infected geographically distinct Aedes aegypti populations | Parasites & Vectors
Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The global distribution and burden of dengue. Nature. 2013;496:504–7. Article CAS PubMed PubMed Central Google Scholar Stanaway JD, Shepard DS, Undurraga EA, Halasa YA, Coffeng LE, Brady OJ, et al. The global burden of dengue: an…
Moderna Reports First Quarter 2023 Financial Results and Provides Business Updates
First quarter 2023 revenues of $1.9 billion; GAAP net income of $79 million and GAAP diluted EPS of $0.19 Company in negotiations for new orders for fall of 2023 in U.S., Japan, and EU, in addition to reiterating 2023 minimum sales expectations of approximately $5.0 billion from previously announced COVID-19…
Machine Learning For Cancer Classification – Part 3
This tutorial is part of a series illustrating basic concepts and techniques for machine learning in R. We will try to build a classifier of relapse in breast cancer. The analysis plan will follow the general pattern (simplified) of a recent paper. This follows from: Machine learning for cancer classification…
Phase 3 PROGRESS Results Highlight Atogepant’s Benefit in Chronic Migraine
Patricia Pozo-Rosich, MD, PhD Weeks after the FDA expanded the indication for atogepant (Qulipta; AbbVie) to include the treatment of chronic migraine, findings presented at the 2023 American Academy of Neurology (AAN) Annual Meeting, held April 22-27, in Boston, Massachusetts, further supported its efficacy. The data presented was from the…
Moderna and Merck look to Phase 3 trial for cancer vaccine and Keytruda treatment
Following the initial announcement of positive Phase 2b KEYNOTE-942 trial results in December 2022, the companies have this week released further data from the trial as they look to the next steps of development. A Phase 3 study is expected to get underway this year, while the companies will also…
Moderna’s (MRNA) mRNA-4157 in combo with Merck’s (MRK) KEYTRUDA reduced the risk of recurrence or death by 44% in melanoma patients
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here. Moderna, Inc. (Nasdaq: MRNA) and Merck (NYSE: MRK) announced the first presentation of detailed results from the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial evaluating mRNA-4157 (V940), an investigational individualized neoantigen therapy (INT), in combination…
Minimal residual disease monitoring in NSCLC
Background Cell-free DNA (cfDNA) refers to fragments of DNA released into the circulation by endothelial cells and white blood cells by active release or passively through apoptosis and necrosis.1,2 The fraction of cfDNA that originates from tumor is known as circulating tumor DNA (ctDNA). In 2016 the first commercial ctDNA…
Gradalis to Participate in the Cantor Fitzgerald Future of Oncology Symposium
Gradalis, Inc. DALLAS, March 29, 2023 (GLOBE NEWSWIRE) — Gradalis, Inc., a privately held, late-stage clinical biotechnology company developing a personalized immunotherapy called Vigil® for patients with ovarian and other cancer tumor types, today announced that Steven Engle, Chief Executive Officer, will participate in a fireside chat at the Cantor…
Early increase in tamoxifen dose in CYP2D6 poor metaboliser breast cancer patients and survival: A propensity score matching analysis
Abstract Purpose Tamoxifen is a drug used for hormone receptor-positive breast cancers, primarily metabolised by the CYP2D6 enzyme into active metabolites such as endoxifen. CYP2D6 displays varying degrees of activity depending on its genotype. This study aims to analyse the effect of an early increase in tamoxifen dose in poor…
Cancer vaccine research may have reached ‘tipping point’
March 22, 2023 10 min read Source/Disclosures Published by: Disclosures: Disis reports being a stockholder/founder of EpiThany; grants from Aston Sci. and Bavarian Nordic during the conduct of the breast cancer vaccine study; serving as editor of JAMA Oncology outside the submitted work; and royalties for a…
Astellas menopause study meets endpoints, leukemia drug doesn’t
There was good and bad news this week from Japanese company Astellas Pharma Inc. as one of its trials yielded positive results, while another didn’t meet its endpoints. Astellas Pharma announced pivotal phase 3 results for its study of fezolinetant, an investigational oral, nonhormonal compound being studied for the treatment…
Astellas and BMT CTN Announce Topline Results from Phase 3 MORPHO Trial of Gilteritinib
TOKYO and ROCKVILLE, Md., March 9, 2023 /PRNewswire/ — Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) today announced topline results from the Phase 3 MORPHO clinical trial evaluating gilteritinib as a maintenance therapy following…
Segmentectomy for ground-glass-dominant lung cancer with a tumour diameter of 3 cm or less including ground-glass opacity (JCOG1211): a multicentre, single-arm, confirmatory, phase 3 trial
Background Although segmentectomy is a widely used surgical procedure, lobectomy is the standard procedure for resectable non-small-cell lung cancer (NSCLC). This study aimed to evaluate the efficacy and safety of segmentectomy for NSCLC up to 3 cm in size, including ground-glass opacity (GGO) and predominant GGO. Methods A multicentre, single-arm,…
isolation forest kaggle – The AI Blog
What Is Isolation Forest Kaggle? Isolation Forest Kaggle is an unsupervised machine learning technique used for identifying anomalies in data sets. It’s based on the idea of isolating a subset of points from the main data set and predicting those points as anomalies if they stray too far away from…
DLBCL therapeutic strategies and gene-oriented treatment
Background Lymphoma is a group of heterogeneous hematological malignancies, which are classified into Hodgkin’s lymphoma (HL) and non-Hodgkin’s lymphoma (NHL). Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive NHL. DLBCL can be divided into germinal center B-cell-like (GCB) subgroup and non-GCB subgroup according to the origin of cells….
Dark microbiome and extremely low organics in Atacama fossil delta unveil Mars life detection limits
Site sampling Main field recognition and sampling of the Red Stone outcrop took place on August, 2019, although subsequent site sampling also took place in February, May, August and October of 2021. After surveying the surroundings, the most continuous exposure was selected to take advantage of the best section traverse…
Early Data for Orca-T Cellular Therapy Provides Basis for Phase 3 Study in AML
The use of the precision cellular therapy Orca-T demonstrated promising efficacy effects at a median follow-up of 1 year in patients with acute leukemia or high-risk myelodysplastic syndrome (MDS) in an early analysis of a phase 1b and 2 study that have yet to be reported, according to data presented…
Phase 3 ZUMA-3 Study of Brexu-cel Elicits Survival Benefit in Relapsed/Refractory B-cell ALL
Findings from subgroup analyses of the phase 3 ZUMA-3 trial (NCT02614066) revealed that treatment with brexucabtagene autoleucel (brexu-cel; Tecartus) generated a survival benefit in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL), regardless of prior lines of treatment, exposure to blinatumomab (Blincyto), or exposure to allogeneic stem cell transplant (alloSCT).1…
Single-cell and bulk transcriptome sequencing identifies two epithelial tumor cell states and refines the consensus molecular classification of colorectal cancer
Cell-type annotation scRNA-seq data were filtered to discard low-quality cells and doublets (Supplementary Fig. 1, Extended Data Fig. 1 and Methods). Supervised clustering (Reference Component Analysis v2 (RCA2)) at low resolution grouped cells into 11 major cell types (Extended Data Fig. 1). To identify epithelial cell subtypes, we initially analyzed…
